On the stock market since 2010, it operates in the world of health and science. It has 1,200 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 24% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
The stock trades 53% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 21% a year on average.
Sales run at $245.4M a year. A small number, but proof the product has real buyers.
A loss of $10.7M against $245.4M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts about 1.2 years. After that, the company needs to find new money.
On our five-subject report card, QIPT sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: QIPT is a high-risk stock — not yet profitable, and its future rides on its product catching on.